SELLAS Life Sciences (SLS) Current Assets (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Current Assets for 17 consecutive years, with $111.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 247.7% year-over-year to $111.2 million; the TTM figure through Mar 2026 stood at $111.2 million (up 247.7% YoY), while the FY2025 annual figure was $75.2 million, up 360.65% from the prior year.
• Current Assets improved to $111.2 million in Q1 2026 per SLS's latest filing, from $75.2 million in the prior quarter.
• Across five years, Current Assets topped out at $111.2 million in Q1 2026 and bottomed at $3.2 million in Q4 2023.
• Historically, Current Assets has averaged $29.9 million across 5 years, with a median of $22.6 million in 2022.
• Annual changes were most pronounced in 2023 — Current Assets sank 82.14% — and 2024, when it soared 414.72%.
• SELLAS Life Sciences' Current Assets stood at $17.8 million in 2022, then plunged by 82.14% to $3.2 million in 2023, then jumped by 414.72% to $16.3 million in 2024, then jumped by 360.65% to $75.2 million in 2025, then jumped by 47.81% to $111.2 million in 2026.
• Business Quant data shows SLS's Current Assets at $111.2 million in Q1 2026, $75.2 million in Q4 2025, and $49.1 million in Q3 2025.